Format

Send to

Choose Destination
Lancet Oncol. 2004 Sep;5(9):541-9.

Molecular therapy in pancreatic adenocarcinoma.

Author information

1
Juravinski Cancer Centre, Hamilton, Ontario Canada. mary.mackenzie@hrcc.on.ca

Abstract

Pancreatic cancer is one of the commonest causes of death from cancer. Despite therapy with surgery, conventional chemotherapy, and radiation, 5-year survival for patients with this diagnosis remains poor. However, advances in the molecular understanding of this malignant disease over the past 5 years might lead to new treatment strategies. Strategies of gene therapy, antiangiogenic treatments, immunotherapy, and signal-transduction inhibition are in preclinical development. This review presents an overview of molecular therapy in pancreatic cancer.

PMID:
15337483
DOI:
10.1016/S1470-2045(04)01565-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center